Seres Therapeutics reports fourth quarter and full year 2017 financial results
Seres Therapeutics reports a net loss of $89.4 million for the 2017 full year, versus a net loss of $91.6 million in 2016. The decrease in the Company’s cash, and equivalents during the quarter was $21.3 million. Seres ended the fourth quarter with $150.0 million in cash, and equivalents. March 08, 2018